2014

An investigation into clozapine prescribing among psychiatrists in Australia

Kerry Dawes
University of Wollongong, kerryd@uow.edu.au

Nagesh B. Pai
University of Wollongong, nagesh@uow.edu.au

Shae-Leigh Vella
University of Wollongong, vella@uow.edu.au

Beverley Rayers
University of Wollongong, brayers@uow.edu.au

Judy Mullan
University of Wollongong, jmullan@uow.edu.au

See next page for additional authors

Publication Details
An investigation into clozapine prescribing among psychiatrists in Australia

Abstract
Abstract of a paper that was presented at the The Royal Australian and New Zealand College of Psychiatrists 2014 New Zealand Conference, 15-17 October, Otago Museum, New Zealand.

Disciplines
Medicine and Health Sciences | Social and Behavioral Sciences

Publication Details

Authors
Kerry Dawes, Nagesh B. Pai, Shae-Leigh Vella, Beverley Rayers, Judy Mullan, and Katie Richardson

This conference paper is available at Research Online: http://ro.uow.edu.au/smhpapers/2290
An Investigation into Clozapine Prescribing Among Psychiatrists in Australia

Background: Clozapine is an effective antipsychotic for the management of treatment-resistant schizophrenia. There is a lack of knowledge of the clozapine prescribing patterns of psychiatrists in Australia.

Objective: The aims of the study were to identify prescribing patterns for clozapine in Australia; identify at what time point and under what circumstances clozapine treatment is initiated in Australia; assess the views of psychiatrists to clozapine treatment; understand reasons why some psychiatrists are reluctant to prescribe clozapine; and identify treatment strategies for patients with schizophrenia who do not or partially respond to clozapine.

Method: A cross-sectional survey was developed using online survey software, and psychiatrists were invited to participate through a monthly edition of the Royal Australian and New Zealand College of Psychiatrists e-Psych online newsletter.

Results: Sixty-two psychiatrists completed the survey, with over 40% of respondents between the ages of 35-44 years, and working in one or a combination of the public, private and tertiary settings. From the survey population, 69% of respondents stated they would commence a patient on clozapine treatment after two unsuccessful trials of other antipsychotics. Twenty-three percent of respondents were reluctant to prescribe clozapine to their patients, and 2 in 5 psychiatrists with greater than ten years' experience, reported a reluctance to prescribe. Leading the reasons for reluctance was the concern that individuals may develop metabolic syndrome, and chronic physical health issues that are associated with weight gain.

Conclusions: The survey responses suggest a need for further investigation into the reasons for disparity between clozapine knowledge and understanding, and the reluctance to prescribe.